Advertisement

Annals of Surgical Oncology

, Volume 26, Issue 10, pp 3141–3151 | Cite as

Perspectives on the Costs of Cancer Care: A Survey of the American Society of Breast Surgeons

  • Rachel A. GreenupEmail author
  • Christel N. Rushing
  • Laura J. Fish
  • Whitney O. Lane
  • Jeffrey M. Peppercorn
  • Emily Bellavance
  • Lisa Tolnitch
  • Terry Hyslop
  • Evan R. Myers
  • S. Yousuf Zafar
  • E. Shelley Hwang
Breast Oncology

Abstract

Background

Cancer treatment costs are not routinely addressed in shared decisions for breast cancer surgery. Thus, we sought to characterize cost awareness and communication among surgeons treating breast cancer.

Methods

We conducted a self-administered, confidential electronic survey among members of the American Society of Breast Surgeons from 1 July to 15 September 2018. Questions were based on previously published or validated survey items, and assessed surgeon demographics, cost sensitivity, and communication. Descriptive summaries and cross-tabulations with Chi-square statistics were used, with exact tests where warranted, to assess findings.

Results

Of those surveyed (N = 2293), 598 (25%) responded. Surgeons reported that ‘risk of recurrence’ (70%), ‘appearance of the breast’ (50%), and ‘risks of surgery’ (47%) were the most influential on patients’ decisions for breast cancer surgery; 6% cited out-of-pocket costs as significant. Over half (53%) of the surgeons agreed that doctors should consider patient costs when choosing cancer treatment, yet the majority of surgeons (58%) reported ‘infrequently’ (43%) or ‘never’ (15%) considering patient costs in medical recommendations. The overwhelming majority (87%) of surgeons believed that patients should have access to the costs of their treatment before making medical decisions. Surgeons treating a higher percentage of Medicaid or uninsured patients were more likely to consistently consider costs (p < 0.001). Participants reported that insufficient knowledge or resources (61%), a perceived inability to help with costs (24%), and inadequate time (22%) impeded cost discussions. Notably, 20% of participants believed that discussing costs might impact the quality of care patients receive.

Conclusions

Cost transparency remains rare, however in shared decisions for breast cancer surgery, improved cost awareness by surgeons has the potential to reduce financial hardship.

Notes

Acknowledgment

This work was supported by the National Institutes of Health Building Interdisciplinary Research Careers in Women’s Health (BIRCWH) Career Development Award (K12HD043446-11). Additional support was provided by the developmental funds of Duke Cancer Institute as part of P30-CA014236 (Office of Cancer Centers, National Cancer Institute).

References

  1. 1.
    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34.CrossRefPubMedGoogle Scholar
  2. 2.
    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30.CrossRefGoogle Scholar
  4. 4.
    Fisher CS, et al. Fear of recurrence and perceived survival benefit are primary motivators for choosing mastectomy over breast-conservation therapy regardless of age. Ann Surg Oncol. 2012;19(10):3246–50.CrossRefPubMedGoogle Scholar
  5. 5.
    Fisher B, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347(16):1233–41.CrossRefGoogle Scholar
  6. 6.
    Veronesi U, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N. Engl. J. Med. 2002;347(16):1227–32.CrossRefPubMedGoogle Scholar
  7. 7.
    Hwang ES, et al. Survival after lumpectomy and mastectomy for early stage invasive breast cancer: the effect of age and hormone receptor status. Cancer. 2013;119(7):1402–11.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Lee CN, et al. Decision making about surgery for early-stage breast cancer. J Am Coll Surg. 2012;214(1):1–10.CrossRefPubMedGoogle Scholar
  9. 9.
    Collins ED, et al. Can women with early-stage breast cancer make an informed decision for mastectomy? J Clin Oncol. 2009;27(4):519–25.CrossRefPubMedGoogle Scholar
  10. 10.
    Lee C, et al. Quality of patient decisions about breast reconstruction after mastectomy. JAMA Surg. 2017;152(8):741–8.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Yabroff KR, et al. Economic burden of cancer in the United States: estimates, projections, and future research. Cancer Epidemiol Biomark Prev. 2011;20(10):2006–14.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Mariotto AB, et al. Projections of the cost of cancer care in the United States: 2010–2020. J Natl Cancer Inst. 2011;103(2):117–28.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Lorenzoni L, Belloni A, Sassi F. Health-care expenditure and health policy in the USA versus other high-spending OECD countries. Lancet. 2014;384(9937):83–92.CrossRefPubMedGoogle Scholar
  14. 14.
    Elkin EB, Bach PB. Cancer’s next frontier: addressing high and increasing costs. JAMA. 2010; 303(11):1086–7.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Zafar Y, et al. Financial distress, communication, and cancer treatment decision making: does cost matter? J Clin Oncol. 2013;31(15 Suppl):6506.Google Scholar
  16. 16.
    Zafar SY, Abernethy AP. Financial toxicity, Part I: a new name for a growing problem. Oncology (Williston Park), 2013;27(2):80–149.Google Scholar
  17. 17.
    Tucker-Seeley RD, Yabroff KR. Minimizing the “financial toxicity” associated with cancer care: advancing the research agenda. J Natl Cancer Inst. 2016;108(5): pii:djv410.Google Scholar
  18. 18.
    Ramsey SD, et al. Financial insolvency as a risk factor for early mortality among patients with cancer. J Clin Oncol. 2016;34(9):980–6.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Kale HP, Carroll NV. Self-reported financial burden of cancer care and its effect on physical and mental health-related quality of life among US cancer survivors. Cancer. 2016;122(8):283–9.CrossRefPubMedGoogle Scholar
  20. 20.
    Schnipper LE, et al. American Society of clinical oncology statement: a conceptual framework to assess the value of cancer treatment options. J Clin Oncol. 2015;33(23):2563–77.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Meropol NJ, et al. American Society of clinical oncology guidance statement: the cost of cancer care. J Clin Oncol. 2009;27(23):3868–74.CrossRefPubMedGoogle Scholar
  22. 22.
    Blumenthal D, McGinnis JM. Measuring Vital Signs: an IOM report on core metrics for health and health care progress. JAMA. 2015;313(19):1901–2.CrossRefPubMedGoogle Scholar
  23. 23.
    Greenup RA, Fish L, Campbell BM, Tolnitch L, Hyslop T, et al. Financial costs and burden related to decisions for breast cancer surgery. J Oncol Pract. in press.Google Scholar
  24. 24.
    Greenup RA, Rushing CR, Fish L, Hyslop T, Peppercorn J, Wheeler SB. The costs of breast cancer care: patient-reported experiences and preferences for transparency. J Clin Oncol. 2018;36(30 Suppl):307.Google Scholar
  25. 25.
    Jagsi R, et al. Treatment decisions and employment of breast cancer patients: results of a population-based survey. Cancer. 2017;123(24):4791–99.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Jagsi R, et al. Long-term financial burden of breast cancer: experiences of a diverse cohort of survivors identified through population-based registries. J Clin Oncol. 2014;32(12):1269–76.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Katz SJ, et al. Surgeon influence on variation in receipt of contralateral prophylactic mastectomy for women with breast cancersurgeon influence on receipt of contralateral prophylactic mastectomysurgeon influence on receipt of contralateral prophylactic mastectomy. JAMA Surg. 2018;153(1):29–36.CrossRefPubMedGoogle Scholar
  28. 28.
    Venetis MK, et al. Social network, surgeon, and media influence on the decision to undergo contralateral prophylactic mastectomy. Am J Clin Oncol. 2018;41(6):519–25.CrossRefPubMedGoogle Scholar
  29. 29.
    Board on Health Care Services, and Institute of Medicine. Charge to the Committee on Improving the Quality of Cancer Care: Addressing the Challenges of an Aging Population. In: Levit L, et al. (eds). Delivering high-quality cancer care: charting a new course for a system in crisis. Washington: National Academies Press; 2013. Copyright 2013 by the National Academy of Sciences. All rights reserved.Google Scholar
  30. 30.
    Greenup RA, Rushing CR, Fish L, Lane W, Peppercorn J, Toolnitch L, et al. Perspectives on the costs of cancer care: a survey of the American Society of Breast Surgeons. Ann Surg Oncol. 2019;26:20–21.CrossRefGoogle Scholar
  31. 31.
    Altomare I, et al. ReCAP: Physician experience and attitudes toward addressing the cost of cancer care. J Oncol Pract. 2016;12(3):247–8.CrossRefPubMedCentralGoogle Scholar
  32. 32.
    Shih YT, Chien CR. A review of cost communication in oncology: patient attitude, provider acceptance, and outcome assessment. Cancer. 2017;123(6):928–39.CrossRefPubMedGoogle Scholar
  33. 33.
    Shih YT, Nasso SF, Zafar SY. Price transparency for whom? In search of out-of-pocket cost estimates to facilitate cost communication in cancer care. Pharmacoeconomics. 2018;36(3):259–61.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Hunter WG, et al. Discussing health care expenses in the oncology clinic: analysis of cost conversations in outpatient encounters. J Oncol Pract. 2017;13(11):e944–e956.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Zafar SY, et al. The utility of cost discussions between patients with cancer and oncologists. Am J Manag Care. 2015;21(9):607–15.PubMedGoogle Scholar
  36. 36.
    Hofstatter EW. Understanding patient perspectives on communication about the cost of cancer care: a review of the literature. J Oncol Pract. 2010;6(4):188–92.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    McFarlane J, Riggins J, Smith TJ. SPIKE$: a six-step protocol for delivering bad news about the cost of medical care. J Clin Oncol. 2008;26(25):4200–4.CrossRefPubMedGoogle Scholar
  38. 38.
    Schrag D, Hanger M. Medical oncologists’ views on communicating with patients about chemotherapy costs: a pilot survey. J Clin Oncol. 2007;25(2):233–7.CrossRefPubMedGoogle Scholar
  39. 39.
    Brick DJ, Scherr KA, Ubel PA. The impact of cost conversations on the patient–physician relationship. Health Commun. 2019;34(1):65–73.CrossRefPubMedGoogle Scholar
  40. 40.
    Bellavance E, et al. Surgeons’ perspectives of contralateral prophylactic mastectomy. Ann Surg Oncol. 2016;23(9):2779–87.CrossRefPubMedGoogle Scholar
  41. 41.
    DeSnyder SM, et al. American Society of breast surgeons’ practice patterns after publication of the SSO-ASTRO-ASCO DCIS consensus guideline on margins for breast-conserving surgery with whole-breast irradiation. Ann Surg Oncol. 2018;25(10):2965–74.CrossRefPubMedGoogle Scholar
  42. 42.
    Boughey JC, et al. Contralateral prophylactic mastectomy (CPM) consensus statement from the American Society of breast surgeons: data on CPM outcomes and risks. Ann Surg Oncol. 2016; 23(10):3100–5.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Boughey JC, et al. Contralateral prophylactic mastectomy consensus statement from the American society of breast surgeons: additional considerations and a framework for shared decision making. Ann Surg Oncol. 2016;23(10):3106–11.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    King TA, et al. Clinical management factors contribute to the decision for contralateral prophylactic mastectomy. J Clin Oncol. 2011;29(16):2158–64.CrossRefPubMedGoogle Scholar
  45. 45.
    Bestvina CM, et al. Patient–oncologist cost communication, financial distress, and medication adherence. J Oncol Pract. 2014;10(3):162–7.CrossRefPubMedGoogle Scholar

Copyright information

© Society of Surgical Oncology 2019

Authors and Affiliations

  • Rachel A. Greenup
    • 1
    • 2
    • 3
    • 5
    Email author
  • Christel N. Rushing
    • 3
    • 4
  • Laura J. Fish
    • 3
    • 5
    • 6
  • Whitney O. Lane
    • 1
  • Jeffrey M. Peppercorn
    • 7
  • Emily Bellavance
    • 8
  • Lisa Tolnitch
    • 1
  • Terry Hyslop
    • 3
    • 4
  • Evan R. Myers
    • 9
    • 10
  • S. Yousuf Zafar
    • 2
    • 3
    • 5
    • 9
  • E. Shelley Hwang
    • 1
    • 3
  1. 1.Department of SurgeryDuke UniversityDurhamUSA
  2. 2.Department of Population Health SciencesDuke UniversityDurhamUSA
  3. 3.Duke Cancer InstituteDuke UniversityDurhamUSA
  4. 4.Department of Biostatistics and BioinformaticsDuke UniversityDurhamUSA
  5. 5.Duke Cancer Control and Population SciencesDuke UniversityDurhamUSA
  6. 6.Duke School of MedicineDuke UniversityDurhamUSA
  7. 7.Department of MedicineMassachusetts General HospitalBostonUSA
  8. 8.University of Maryland School of MedicineBaltimoreUSA
  9. 9.Department of MedicineDuke UniversityDurhamUSA
  10. 10.Department of Obstetrics and GynecologyDuke UniversityDurhamUSA

Personalised recommendations